The prognosis of patients with inoperable locally advanced or residual/relapsed gastric cancer is rather poor. Concurrent capecitabine chemoradiotherapy is safe and recommended. Nimotuzumab, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody, has shown its antitumor safety and efficiency in many phase I/II studies. Efficiency of combination of these treatment need to be further analyzed.

There is no standard treatment for patients with inoperable locally advanced or residual/relapsed gastric cancer. For the former ones, 5-fluorouracil(5-FU) based concurrent chemoradiotherapy is a recommended treatment regimen. Concurrent capecitabine chemoradiotherapy showed similar results. So far, more and more studies have shown that drugs targeting at EGFRs play an important role in antitumor treatment. Nimotuzumab, an anti-EGFR monoclonal antibody, has shown its safety and efficiency in many phase I/II studies. Because of poor survival of patients with inoperable locally advanced or residual/relapsed gastric cancer, the efficiency of nimotuzumab plus concurrent capecitabine chemoradiotherapy need to be further analyzed.

Inclusion Criteria:

• 18-75 years old, male or female
• Gastric cancer with measurable lesions, and the diameter is at least 1 cm
• Karnofsky score: at least 70
• Estimated survival: at least 6 months
• No prior target therapy or radiotherapy
• No severe hypertension, cardiac disease, or diabetes mellitus
• Normal blood routine and chemical tests
• Signed consent

Exclusion Criteria:

• Other malignancies simultaneously except in situ cervix or non-melanoma skin cancer
• Extensive distant metastases
• Pregnancy or in lactation
• Allergic to 5-Fluorouracil